Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PD-L1 status and aggressive clear cell RCC

Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007

Key clinical point: PD-L1 positive status in the tumor and negative status in the thrombus is linked to aggressive behavior in clear cell renal cell carcinoma.

Major finding: PD-L1 immunostaining was positive in at least one of the three samples of the main tumor in 22 of 39 advanced clear cell renal cell carcinomas. Cases that lost PD-L1 positivity in the thrombus (18 cases), were of higher grade (Fisher's exact test, P = 0.01) and higher AJCC pT category (Cochran Armitage, P = 0.02) than the cases that were positive both in tumor and thrombus (4 cases). A high variability in PD-L1 positivity was noted across three different areas of the main tumor tested. This variability should be kept in mind when selecting the tumor samples to be tested for determining immunotherapy.

Study details: An analysis of PD-L1 (SP142) expression in three different areas of the tumor and in two areas of the renal vein/caval thrombi in 39 advanced clear cell renal cell carcinomas.

Disclosures: The researchers reported no relevant financial disclosures.

Source: Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007

Citation:

Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007

This Week's Must Reads

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.

Must Reads in Renal Cell Carcinoma

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.